[Ticlopidine-induced aplastic anemia. A case report and review of the literature].
Ticlopidine, an inhibitor of platelet aggregation, is widely used for peripheral arterial disease. The use of this drug has been associated with neutropenie and other adverse hematologic effects. Aplastic anemie is a rate complication that carries high mortality. We describe the case of a 91 years old woman with ticlopedine-induced aplastic anemia. The patient was treated with filgrastim brood spectrum antibiotics and other general supportive care measures. Despite initial improvement the old woman died 7 weeks after admission for septic shock. A review of medical literature revealed 24 similar cases. Filgrastim has been used previous by with variable success.
Unità Operativa Geriatria, Ospedale Civile Santa Chiara, A.P.S.S., Trento.
Roberto
R
Bortolotti
Maria
M
Savino
Gabriele
G
Noro
D000368:Aged; D000369:Aged, 80 and over; D000741:Anemia, Aplastic / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000401:mortality; D001772:Blood Cell Count; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D011994:Recombinant Proteins; D013988:Ticlopidine / Q000009:adverse effects*; D013997:Time Factors
D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D013988:Ticlopidine; D000069585:Filgrastim